VENUS: Septic Gene Expression Using SeptiCyte

Status:	Completed
Conditions:	Infectious Disease, Hospital
Therapuetic Areas:	Immunology / Infectious Diseases, Other
Healthy:	No
Age Range:	18 - 89
Updated:	8/22/2018
Start Date:	April 2014
End Date:	December 2016

VENUS: Validation of Septic Gene ExpressioN Using SeptiCyte®

The investigators seek to evaluate a new test for determining presence of infection/sepsis as
compared to non-infection/systemic inflammatory response syndrome among critically ill
patients within the first 24 hours of their being hospitalized in an intensive care unit
(ICU) within the first 7 days of hospitalization. The primary purpose of the study is to
validate SeptiCyte® Lab in this population as compared to: 1) the doctor's impression and 2)
existing clinical parameters. The investigators also hope to assess how well a related, new
blood test, SeptID® identifies different types of infection, as compared to cultures and
other lab tests.

Inclusion Criteria:

1. 18-89 years old on the day of ICU admission

2. SIRS present as defined by the presence of two or more of the following:

- Temperature > 38°C or < 36°C

- Heart Rate > 90 beat/min

- Tachypnea > 20/min or PaCO2 < 32 mmHg

- White Blood Cell count > 12 000/mm3 or < 4 000/mm3 or > 10% immature neutrophils
(bands)

Exclusion Criteria:

1. Consent not provided

2. Age less than 18 or greater than 89 years old on the day of ICU admission

3. Not admitted to ICU

4. Clinical cultures or serologies not obtained

5. Subject has been admitted to study hospital (or transferring facility) for ≥ 24 hours

6. Elective cardiac surgery patients with an expected duration in ICU of less than 24
hours.

7. Patients on non-prophylactic antibiotics for more than 24 hours prior to ICU admission

8. Delay of >24 hours between trial enrollment and sample draw time

9. Ethnic/racial category has completed enrollment.

We found this trial at

sites

Intermountain Medical Center

5121 S Cottonwood St
Murray, Utah 84157

(801) 507-7000